Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA4167 | CA9938 | U.S. | 1999 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 156 |
| 2 | 3TC+AZT | 21 |
| 3 | 3TC+AZT+RTV | 39 |
| 4 | 3TC+D4T+SQV | 13 |
| 5 | 3TC+D4T+RTV | 43 |
| 6 | D4T+NVP+NFV | 21 |
| 7 | DDI+EFV+NVP | 17 |
| 8 | DDI+EFV+IDV+RTV | 16 |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| D67N, T69D, K70R, L74V, T215F | K219Q | Y181C, G190A | V179D | E79D, A98S, K122E, Q174R, G196E, T200A, E203K, Q207E, D218E, T240TA, V245K, T286A, A288T, V292I, E297K |
| >CA9938| codons 1-303 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPV FAIKKKNSDRWRKVVDFRDLNKRTQDFWEVQLGIPHPSGLKKKKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKRNPDIDI CQYMDDLYVASDLEIEQHRAKIKELREHLLRWGFFTPEQKHQKEPPFLWMGYELHPDKWA VQPIKLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKTLTEIIPLTKEAE LEL |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| I54V, V82A, L90M | F53L, G73GC | L10I, I15V, K20R, M36I, N37D, K55R, D60E, I62V, L63P, A71V, I72E, Q92QR |
| >CA10004| codons 1-99 PQITLWQRPIVTIKVGGQLREALLDTGADDTVLEEIDLPGRWKPKMIGGIGGLVRVRQYE QVPIEICGHKVECTVLVGPTPANIIGRNLMTRIGCTLNF |
References
| Author | Title | Citation |
| Gonzales, MJ | HIV-1 reverse transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a Northern California clinic-based population. | J Infect Dis, 2001 |
| Gonzales, MJ | Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. | AIDS, 2003 |
| Gonzales, MJ | Protease and reverse transcriptase mutation patterns in HIV-1 isolates from heavily treated persons: comparison of isolates from northern California with isolates from other regions. | ARHR, 2003 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |